Tag: FY26
Will Vi survive beyond FY26? Court petition says it may not
“It is humbly submitted that...
Piramal Pharma CDMO growth hit by US policy jitters; recovery seen in FY27 | Company Business News-OxBig News Network
Piramal Pharma anticipates muted, single-digit growth for its contract development and manufacturing organization (CDMO) business in FY26, hurt by near-term uncertainties as clients defer...
Tata Power to spend ₹25,000 crore as capex in FY26, two discom bids eyed in UP: CEO Praveer Sinha | Company Business News
Tata Power is looking to spend ₹25,000 crore as capital expenditure (capex) in FY26 and the company is also keen to bid for...
Biocon sees mid-teens revenue growth on biosimilars, generics push | Mint
Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in...
